JP2017513866A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513866A5
JP2017513866A5 JP2016563193A JP2016563193A JP2017513866A5 JP 2017513866 A5 JP2017513866 A5 JP 2017513866A5 JP 2016563193 A JP2016563193 A JP 2016563193A JP 2016563193 A JP2016563193 A JP 2016563193A JP 2017513866 A5 JP2017513866 A5 JP 2017513866A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
composition
administration
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016563193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513866A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/034778 external-priority patent/WO2015163840A1/en
Publication of JP2017513866A publication Critical patent/JP2017513866A/ja
Publication of JP2017513866A5 publication Critical patent/JP2017513866A5/ja
Pending legal-status Critical Current

Links

JP2016563193A 2014-04-21 2014-04-21 パーキンソン病の運動症状変動の迅速な緩和 Pending JP2017513866A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/034778 WO2015163840A1 (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019039444A Division JP2019108379A (ja) 2019-03-05 2019-03-05 パーキンソン病の運動症状変動の迅速な緩和

Publications (2)

Publication Number Publication Date
JP2017513866A JP2017513866A (ja) 2017-06-01
JP2017513866A5 true JP2017513866A5 (cg-RX-API-DMAC7.html) 2019-04-25

Family

ID=54332876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016563193A Pending JP2017513866A (ja) 2014-04-21 2014-04-21 パーキンソン病の運動症状変動の迅速な緩和

Country Status (14)

Country Link
US (2) US20170296498A1 (cg-RX-API-DMAC7.html)
EP (2) EP3831375A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017513866A (cg-RX-API-DMAC7.html)
KR (2) KR20170008754A (cg-RX-API-DMAC7.html)
CN (2) CN113209055A (cg-RX-API-DMAC7.html)
AU (2) AU2014391721B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016024502A8 (cg-RX-API-DMAC7.html)
CA (1) CA2946165C (cg-RX-API-DMAC7.html)
IL (2) IL309959A (cg-RX-API-DMAC7.html)
MX (1) MX2016013741A (cg-RX-API-DMAC7.html)
RU (1) RU2698330C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201608608PA (cg-RX-API-DMAC7.html)
WO (1) WO2015163840A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201607833B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
CA3087696A1 (en) * 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of levodopa powder by precision olfactory device
JP2021532098A (ja) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
JP4384503B2 (ja) * 2002-03-20 2009-12-16 アルカーメス,インコーポレイテッド レボドパの肺送達
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2008156586A2 (en) 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
RU2496494C2 (ru) * 2008-06-30 2013-10-27 Новартис Аг КОМБИНАЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ mGluR, ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ПАРКИНСОНА
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
BR112015009088A2 (pt) * 2012-10-22 2017-07-04 Civitas Therapeutics Inc formulações de levodopa para alívio rápido da doença de parkinson.
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use

Similar Documents

Publication Publication Date Title
AU2025204271A1 (en) Microcrystalline diketopiperazine compositions and methods
JP2013224331A5 (cg-RX-API-DMAC7.html)
JP2011520911A5 (cg-RX-API-DMAC7.html)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2016534153A5 (cg-RX-API-DMAC7.html)
EA033113B1 (ru) Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
MX2013015005A (es) Microparticulas de dicetopiperazina de alta capacidad.
HK1201475A1 (en) Methods and compositions for treating pain
HK1203149A1 (en) Novel dosage form and formulation of abediterol
JP2012193216A5 (cg-RX-API-DMAC7.html)
JP2014528474A5 (cg-RX-API-DMAC7.html)
JP2018528966A5 (cg-RX-API-DMAC7.html)
EA201591869A1 (ru) Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой
JP2017105859A5 (cg-RX-API-DMAC7.html)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2012502047A5 (cg-RX-API-DMAC7.html)
JP2018527386A5 (cg-RX-API-DMAC7.html)
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
JP2017105862A5 (cg-RX-API-DMAC7.html)
JP2016512247A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2017513866A5 (cg-RX-API-DMAC7.html)
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
JP2021510682A5 (cg-RX-API-DMAC7.html)
JP2019507786A5 (cg-RX-API-DMAC7.html)